Sarepta Therapeutics, Inc. (SRPT)
NASDAQ: SRPT · Real-Time Price · USD
15.50
-0.27 (-1.71%)
Jun 16, 2026, 10:32 AM EDT - Market open
Sarepta Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 464.45 | 801.28 | 1,103 | 428.43 | 966.78 | 2,116 |
Short-Term Investments | 188.74 | 138.37 | 251.78 | 1,248 | 1,023 | - |
Cash & Short-Term Investments | 653.19 | 939.65 | 1,355 | 1,676 | 1,989 | 2,116 |
Cash Growth | 24.95% | -30.64% | -19.18% | -15.74% | -5.98% | 9.15% |
Accounts Receivable | 394.82 | 398.23 | 601.99 | 400.33 | 214.63 | 152.99 |
Inventory | 1,001 | 914.74 | 749.96 | 322.86 | 203.97 | 186.21 |
Other Current Assets | 260.76 | 285.31 | 366.72 | 179.9 | 149.89 | 149.03 |
Total Current Assets | 2,310 | 2,538 | 3,073 | 2,579 | 2,558 | 2,604 |
Net Property, Plant & Equipment | 460.3 | 470.62 | 488.65 | 357.11 | 244.99 | 236.69 |
Other Intangible Assets | - | - | - | - | - | 14.24 |
Long-Term Investments | 81.94 | 1.05 | 133.16 | - | - | - |
Other Long-Term Assets | 326.82 | 340.1 | 267.9 | 328.14 | 325.51 | 292.95 |
Total Assets | 3,179 | 3,350 | 3,963 | 3,265 | 3,128 | 3,148 |
Accounts Payable | 70.38 | 280.84 | 214.44 | 164.92 | 95.88 | 76.74 |
Accrued Expenses | 302.37 | 359.66 | 373.51 | 315 | 419 | 271.7 |
Current Portion of Long-Term Debt | - | - | - | 105.48 | - | - |
Current Portion of Leases | - | - | - | - | 15.49 | - |
Unearned Revenue | 116.04 | 443.4 | 130.26 | 50.42 | 89.24 | 89.24 |
Other Current Liabilities | 10.38 | 11.39 | 13.47 | 17.85 | - | 15.05 |
Total Current Liabilities | 499.16 | 1,095 | 731.68 | 653.66 | 619.6 | 452.73 |
Long-Term Debt | 838.16 | 828.97 | 1,137 | 1,133 | 1,544 | 1,097 |
Long-Term Leases | 198.51 | 199.38 | 192.47 | 140.97 | 57.58 | 41.51 |
Other Long-Term Liabilities | 138 | 85.44 | 374.15 | 478.1 | 521.94 | 628.84 |
Total Long-Term Liabilities | 1,175 | 1,114 | 1,704 | 1,752 | 2,124 | 1,767 |
Total Liabilities | 1,674 | 2,209 | 2,435 | 2,405 | 2,743 | 2,220 |
Common Stock | 0.01 | 0.01 | 0.01 | 0 | 0.01 | 0.01 |
Treasury Stock | -25.26 | -25.26 | - | - | - | - |
Additional Paid-in Capital | 6,077 | 6,043 | 5,739 | 5,305 | 4,297 | 4,135 |
Accumulated Other Comprehensive Income | -0.12 | 0.27 | -0.22 | 0.92 | -1.66 | -0.02 |
Retained Earnings | -4,546 | -4,877 | -4,211 | -4,446 | -3,910 | -3,207 |
Shareholders' Equity | 1,505 | 1,141 | 1,528 | 859.34 | 384.95 | 928.01 |
Total Liabilities & Equity | 3,179 | 3,350 | 3,963 | 3,265 | 3,128 | 3,148 |
Total Debt | 1,037 | 1,028 | 1,330 | 1,379 | 1,617 | 1,138 |
Net Cash (Debt) | -383.48 | -88.7 | 25.2 | 297.29 | 372.02 | 977.48 |
Net Cash Growth | - | - | -91.53% | -20.09% | -61.94% | 12.91% |
Net Cash Per Share | -3.54 | -0.89 | 0.23 | 3.22 | 4.25 | 12.03 |
Book Value | 1,505 | 1,141 | 1,528 | 859.34 | 384.95 | 928.01 |
Book Value Per Share | 13.89 | 11.39 | 14.16 | 9.30 | 4.40 | 11.42 |
Tangible Book Value | 1,505 | 1,141 | 1,528 | 859.34 | 384.95 | 913.77 |
Tangible Book Value Per Share | 13.89 | 11.39 | 14.16 | 9.30 | 4.40 | 11.24 |